Stichworte: | Chinaproject | Recht |Wirtschaft |Steuern |Events |News|  



 
by FreeFind

 

Home

Impressum

Inhalt

Kontakt

Recht

Wirtschaft

Steuern

Jobs

Ihr Beitrag

News

Events

 

Newsletter: Chinese Health & Medicine by Lehman, Lee & Xu , Beijing

CHINA HEALTH SCIENCES NEWSLETTER

TOPICS THIS ISSUE:

  • Government Gets Tough on Drug Manufacturers

  • Pharmaceutical Industry Preparing for WTO Competition

  • Counterfeiting in the Pharmaceutical Industry

  • Government Comments On Medical Insurance, Health and Drug Industry

  • Tenth 5 Year Plan for the Pharmaceutical Industry

  • 68 China Pharmaceutical Enterprises on the Stock Market

  • List of China GMP Facilities (Continued)

Government Gets Tough on Drug Manufacturers

Law enforcement chiefs cracked some 480,000 cases of manufacturing and marketing of counterfeit drugs with a market value of RMB 470 million (US $56.8 million) last year.

Zheng Xiaoyu, director of the State Drug Administration, disclosed the statistics during a group discussion at the ongoing session of the Ninth National People's Congress (NPC). He said that more than 1,300 manufacturers were forced to halt production to allow for restructuring to meet the national quality standards, and more than 8,600 illegal drug distributors were permanently shut down.

The government has pledged to reinforce its zero tolerance campaign on unqualified or illegal medicine manufacturers, and will "be very cautious over the establishment of new plants" in a bid to regulate the market.

"The State Council has paid great attention to the issue of counterfeit drugs in the market. We have reformed our supervision system to fortify control over the market since last year," Zheng said.

Zheng said the administration will shut down about half of existing healthcare product manufacturers this year, leaving approximately only 1,300.

"These manufacturers, which have sneaked into the market due to slack government control, fail to meet the national quality standard. They must be closed to prevent rampant counterfeits and unqualified products from going on sale to the public," added Zheng.

(Source: china.org.cn)

Pharmaceutical Industry Preparing for WTO Competition

Chinese medicine distributors have three years before their foreign counterparts can freely enter the market.

According to China's commitments to the World Trade Organization, the medicine retail and wholesale business will be opened to foreign investors with no capital or geographical limitations within three years of China's December 2001 WTO entry.

During the three-year waiting period, joint-venture trials will be limited in the key cities of Beijing, Guangzhou and Shanghai. Under the trials, any foreign trader can apply to the State Economic and Trade Commission to set up a joint venture if the company's assets reached US$ 200 million the year before the application and the annual turnover reached at least US$2 billion in each of the previous three years.

Companies in China's central and western regions will have a lower threshold. For joint-venture wholesalers, the Chinese partner must own at least 51 per cent of the venture.

The majority of China's medicine-distribution enterprises are not competitive. The industry has been hampered by government control for decades and different pharmacies began merging into chain stores in only the past five years.

By the end of last year, the number of authorized drug wholesalers in China reached 17,000 with 120,000 retailers. In the United States, there are 50,000 medicine retailers but as few as 70 wholesale companies.

Wang Jinxia, chairman of the China Medicine Commercial Association, said the industry is crowded with small companies but is short of conglomerates.

Yu Mingde, deputy director of the State Economic and Trade Commission's Economic Operations Bureau said that to face the coming challenges, the government will encourage mergers in the sector, and key enterprises will be encouraged to build large enterprise groups.

Yu predicted that 10 conglomerates will emerge in the next five years, each with more than 1,000 outlets and a turnover of RMB 5 billion (US$ 604 million). Chinese medicine distributors have three years to improve their performance before foreign distributors can freely enter the market.

To date, more than 60 of the domestic companies attempting to get a stronger foothold on the national pharmaceutical market have been granted approval to operate branches nationwide.

(Source: China Daily) 

Profitable China GMP Facilities for Sale
Send email to mail@chinalaw.cc for further information.

 Counterfeiting in the Pharmaceutical Industry

Although the Chinese press is not blind to counterfeit or sub-standard drugs and pharmaceuticals, the focus usually remains on local victims of the trade, and does not often concentrate on the manufacturers themselves.

In 1996, when sub-standard medicine killed 89 children in Haiti, it was found that the source of the medicine was a trading company in China. How exactly the anti-freeze was used in the medicine remains a mystery due to the complexity and vagueness of the transactions. However, the Haiti case remains a scary reminder of the presence of counterfeiting in the pharmaceutical industry in China.

Raids on Chinese warehouses regularly turn up export bound cartons filled with fake drugs labeled with multinational trademarks, and State Owned Enterprises (SOEs) are known to manufacture and export counterfeits.

As the profits from selling counterfeit medicines can often be as high as the sale of narcotic drugs, it is thought that organized crime has become involved in the China fake drug industry. Harvey Bale, Director-General of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), said that organized crime faces "less risk in moving into counterfeit medicines than illegal drugs."

Some counterfeiters even appear to have government protection as officials and People's Liberation Army (PLA) members, who supposedly were previously involved in the actual manufacturing and distribution of the drugs, tip counterfeiters off about upcoming raids.

While companies are increasingly using sophisticated anti-counterfeiting methods, such as holograms, embossed logos and sealed packets for their drugs, counterfeiters are becoming equally sophisticated in the use of high technology to copy the anti-counterfeiting mechanisms.

Some estimates suggest that the counterfeit pharmaceutical goods market in the United States alone amounts to between US $16 and US $48 billion. In China, the situation is much more desperate with half of some types of drugs being counterfeit in the China market.

(Source: World Markets Analysis)

Government Comments On Medical Insurance, Health and Drug Industry

China's medical insurance program extended benefits to about 76.3 million employees last year. The Ministry of Labor and Social Security said that due to effective methods undertaken by the government, the number of employees covered by medical insurance had increased by 32.98 million in 2001.

In 2002, the government hopes to expand its medical insurance program to cover employees in foreign-invested and private firms.

Ministry officials also said that firms should be paying their employees' medical insurance premiums and if they are found to be not doing so, they will be punished.

China's health and drug authorities have also begun a nationwide campaign against the re-use, production and marketing of brand-imitation and substandard disposable syringes and other medical devices.

The Ministry of Health requested that all hospitals and medical units only use standard medical instruments and do their best to prevent any discarded instruments from being re-used or re-marketed.

The ministry is drafting a new set of regulations on how to prevent cross-infection between hospitals. The draft will set up detailed and strict rules on the purchasing, use and destruction of disposable medical instruments.

Official statistics show that about 5,000 firms make medical instruments in China, with a total output of RMB 30 billion (US$ 3.6 billion) a year and an average growth rate of 18% .

(Source: HK Edition)

Tenth 5 Year Plan for the Pharmaceutical Industry

According to the tenth 5-year plan (2001-2005) set for the development of the pharmaceutical industry, China will maintain the following annual growth rates in the next 5 years up to 2005. They are:

(1) Gross industrial output value (+12%)
(2) Industrial added value (+13%)
(3) Gross commercial sales volume (+9%)
(4) Import and export volume (+6%)
(5) Industrial profit (+13%)

According to industry experts' forecast, China's demand for drugs will rise by 12% annually to reach RMB 218 billion or US$ 26.37 billion by 2005.

(Source: Asia Market Intelligence: Business Consulting Division)

68 China Pharmaceutical Enterprises on the Stock Market

The State Drug Administration reported that 68 of the 6,700 pharmaceutical enterprises in China have been listed on the stock market. Of the 68 companies, there are 20 chemical drug producers, 27 traditional drug producing and distributing enterprises, 16 biomedical enterprises and 5 medical apparatuses makers.

According to the State Economic and Trade Commission, there are now a total of 1, 800 foreign invested pharmaceutical enterprises established in China. These firms involved contractual investments totaling US $5.57 billion including US $2.75 billion of foreign funds.

(Source: Asia Market Intelligence: Business Consulting Division) 

China Pharma Distribution Company for Sale
Send email to mail@chinalaw.cc for further information.

 List of China GMP Facilities (Continued)

Name of Enterprise

Certified Scope

851. Zhejiang Xinchang-jingxin Pharma Co., Ltd.

Tablet, Capsule

852. Zhejiang kangyu Pharmaceutical Co., Ltd.

Tablet, Capsule

853. Hunan Jiuzhidang Co., Ltd. by Shares

CTM pill

854. Nanjing Dongyuan Pharma Co., Ltd.

Capsule, Tablet, Granule, Powder-injection

855. Hubei Furen Pharma Co., Ltd. by Shares

Capsule, Granule

856. Beihai Jiqi-fangzhou Genetic-Pharma Co., Ltd.

Rhg-CFS

857. Tianjin Zhongyang Pharma Co., Ltd.

Capsule, Tablet, Granule

858. Shanghai Xinyi Pharma Co., Ltd.

Tablet, Capsule

859. Shandong Lukang Pharma Group Luyuan Company

Powder-injection, Oral liquid, Bulk

860. Shanghai Xinyi Pharma Co., Ltd.

Capsule, Powder

861. Shandong Lukang Pharma Group Luyuan Company

Capsule

862. Shandong Lukang Pharma Group Luyuan Company

Tablet

863. Shanghai Bio-product Research Institute of MOH

Vaccine

864. Zhejiang Xinchang Pharmaceutical Factory

High dose injection

865. SASS Pharmaceutical Co., Ltd.

Injection

866. Guizhou Shenqi Pharmaceutical Co., Ltd.

Tablet, Capsule

867. Shijiazhuang 4th Pharmaceutical Co., Ltd by Shares

High dose injection

868. Shandong Greenleave Pharmaceutical Co., Ltd. by Shares

Tablet, Capsule, Granule

869. Wuhan Zhonglian Pharmaceutical Factory

Syrup, Granule, Tablet, Pill

870. Hebei Union Pharmaceutical Co., Ltd.

Bulk (Penicillin)

871. Zhejiang Jimin Pharmaceutical Co., Ltd.

High dose injection

872. Hebei Pharmaceutical (Group) Co., Ltd.

Bulk (Penicillin )

873. Zhejiang 999- Bangbaikang Co., Ltd.

Freeze-dried Powder-injection, Low dose injection

874. Hangzhou Sanofi-Mingsheng Pharmaceutical Co., Ltd.

Tablet, Capsule, Granule, Powder

875. Inner Mongolia Ganqika Pharma Factory

High dose injection, low dose injectionTablet, Capsule, Powder-injection

876. Beijing 3rd Pharmaceutical Factory

Low dose injection, bulk

877. Beijing 3rd Pharmaceutical Factory

Eye-drops

878. Henan Huixin Pharmaceutical Co., Ltd.

Oral liquid

879. Beijing Taide Pharmaceutical Co., Ltd. by Shares

Low dose injection

880. Upjohn Suzhou Pharmaceutical Co., Ltd.

Tablet, Capsule

881. Shanxi Jinhua Pharmaceutical Co., Ltd.

Tablet, Capsule

882. Jiangxi Dongya Pharmaceutical Co., Ltd.

High dose injection

883. Sichuan Changzheng Pharmaceutical Co., Ltd.

Powder-injection

884. Shandong Ahua Bio-pharma Co., Ltd.

recombinant human hematopoitin

885. Shanghai Abbott Pharmaceutical Co., Ltd

Tablet, Granule, Inhalant

886. Zhejiang Pinghu Pharmaceutical Factory

High dose injection

887. Shangshai Dongxi Bio-tech Co., Ltd.

Rhg-CFS

888. Zhejiang Wanma Pharma Co., Ltd.

Freeze-dried Powder-injection

889. Huainan Fushou Pharmaceutical Co., Ltd.

Rhg-CFS

890. Hainan Haifu Pharmaceutical Co., Ltd.

Tablet, Capsule, Granule

891. Guangzhou Chenliji Pharmaceutical Factory

Capsule

892. Xiehe Pharmaceutical Co., Ltd.

Tablet, Capsule, Granule

893. Guizhou Hanfang Pharmaceutical Co., Ltd.

Granule, Capsule

894. Suzhou 2nd Pharmaceutical Factory

Powder-injection, Capsule

895. 999 Pharmaceutical Co., Ltd. by Shares

Ointment

896. Shandong Huaifang Pharmaceutical Group Co., Ltd.

Exosomatic diagnose agent

897. Shanghai Meiyou Pharmaceutical Factory

Tablet, Capsule, Granule

898. Shenzhen Pharmaceutical Factory

Oral liquid

899. Hangzhou Zhongmei East-China Pharmaceutical Co., Ltd.

Capsule

900. Jiangsu Yangzijiang Jiangyao Pharmaceutical Group Company

High dose injection, Low dose injection, Oral liquid


Lehman Lee & Xu

China Lawyers, Notaries, Patent, Copyright and Trademark Agents

http://www.chinalaw.cc/

Beijing Office

Shanghai Office

6th floor, Dongwai Diplomatic Office Building
23 Dongzhimenwai Dajie
Beijing 100600 China
Tel.: (86)(10) 8532-1919
Fax: (86)(10) 8532-1999
Email: mail@chinalaw.cc

Suite 5107, Plaza 66
No. 1266, West Nanjing Road
Shanghai 200040 China

Tel: (86)(21) 6375-8240

Fax:(86)(21) 6375-8705
Email: shanghai@chinalaw.cc

Shenyang

Hong Kong

Guangzhou

Chengdu

To unsubscribe from this newsletter send an email to
unsub-hs@lehmanlaw.comPlease include the email address to which the newsletter is being sent (not a forwarded address) in the body of the email.

back to Chinese Medicine


Home - Kontakt - Submit Website - News - Travel - Kalender - Mitgliedschaft - Online-Beratung


Chinaproject.de - Suche - Inhalt - Impressum - Newsletter - Recht - Wirtschaft - Steuern


© 2001, Chinaproject.de, Spichernstraße 15, 10777 Berlin, Tel. 01723116595, Fax. 030-2185432 - All rights reserved for the Author/Publisher. Alle Rechte, auch Übersetzungen, sind vorbehalten. Reproduktionen gleich welcher Art, ob Fotokopie, Mikrofilm oder Erfassung in Datenbanken oder Datenbankverarbeitungsanlagen nur mit schriftlicher Genehmigung des Urhebers. Aus der Veröffentlichung kann nicht geschlossen werden, daß die beschriebenen Lösungen oder verwendeten Bezeichnungen frei von gewerblichen Urheber oder Schutzrechten sind. Verantwortlich: Eberhard J. Trempel,  apfb@chinaproject.de - Nachdruck und Weiterverbreitung, auch auszugsweise, nur mit Genehmigung der Redaktion. Netscape and Microsoft browsers are supported from version 4.0 upward on Windows and from version 4.5 on the Macintosh. We have done our best to make the site accessible with a wide range of browsers but cannot guarantee optimum viewing with all of them.